Related Experiment Video

Updated: Jul 16, 2026

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Geranylgeranylacetone inhibits ovarian cancer progression in vitro and in vivo

Kae Hashimoto1, Ken-ichirou Morishige, Kenjiro Sawada

  • 1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.

Biochemical and Biophysical Research Communications
|March 9, 2007
PubMed

Insights

Geranylgeranylacetone (GGA) inhibits ovarian cancer progression by suppressing cell proliferation and tumor growth. This anti-tumor effect is linked to the inactivation of Rho, Ras, and mitogen-activated protein kinase (MAPK) pathways.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Geranylgeranylacetone (GGA), an isoprenoid, is an anti-ulcer drug.
  • Previous research indicated GGA inhibits ovarian cancer invasion via Rho activation attenuation.

Purpose of the Study:

  • To investigate the effects of GGA on ovarian cancer progression in vitro and in vivo.
  • To elucidate the molecular mechanisms underlying GGA's anti-tumor activity.

Main Methods:

  • In vitro and in vivo ovarian cancer models were utilized.
  • Analysis included cell proliferation assays, Rho activation assays, Ras inactivation assessment, and mitogen-activated protein kinase (MAPK) tyrosine phosphorylation measurement.

Main Results:

  • GGA treatment inhibited ovarian cancer cell proliferation in vitro.
  • GGA suppressed tumor growth and ascites formation in vivo.
  • GGA led to Ras inactivation and suppressed MAPK tyrosine phosphorylation.

Conclusions:

  • GGA demonstrates anti-cancer effects against ovarian cancer progression.
  • GGA's anti-tumor mechanism involves the suppression of Rho, Ras, and MAPK activation pathways.

More Related Videos

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...